Clinical trial · Observational
A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal
Preferences Of Patients And Oncologists For The Characteristics Of The Treatment For RCC In Spain And Portugal
NCT05168436CI-TRIAL-00055651completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this observational study is to determine patients' and professionals' preferences for the characteristics (attributes) of the treatment for Renal cell carcinoma (RCC) in Spain and Portugal.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- Participants with renal cell carcinoma (RCC) treated with nivolumab
- label
- Cohort 2
- description
- Oncologists with expertise in renal cancer from Spain and Portugal
Primary outcomes (2)
- measure
- Utility: Renal cell carcinoma (RCC) participants' preferences
- timeFrame
- At Baseline
- description
- Utility (preference score) derived for a treatment alternative choice (scenario)
- measure
- Utility: Oncologists' preferences
- timeFrame
- At Baseline
- description
- Utility (preference score) derived for a treatment alternative choice (scenario)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: Oncologists from Spain and Portugal will be identified by the promoter and invited to participate in the study in accordance with the inclusion criteria described below. * The oncologist is currently working in a Spanish or Portuguese public hospital. * The oncologist has at least 2 years of experience in the management of participants with Renal Cell Carcinoma (RCC). * The oncologist has agreed to participate in the study. Participants with a diagnosis of RCC will be identified and recruited by the Principal Investigators of the study, taking into account the inclusion criteria described below. * The participant has been diagnosed with RCC for a minimum of 2 months before study inclusion. * The participant has received or is currently receiving pharmacological treatment for RCC; * The participant has provided the informed consent to participate in the study. * The participant must be able to read, understand and complete the survey instrument according to the judgment of the responsible physician. Exclusion Criteria: • Not applicable
References
Publications (0)
Data not yet available
No reference posted for this study.